Apricus Won't Need New Trials To Resubmit ED Cream Vitaros At FDA
Executive Summary
After feedback on a very old complete response, biotech plans to resubmit a filing in the second half of 2017, instead of the fourth quarter, and will need to engage the Office of Product Quality because Vitaros is viewed as a drug/device combination.